Indolent Lymphoma  Pipeline Review, H2 2012

Indolent Lymphoma Pipeline Review, H2 2012

Oct 2012 Global Markets Direct Lymphoma155 Pages Price :
$ 2000

Indolent Lymphoma Pipeline Review, H2 2012

Global Markets Directs, 'Indolent Lymphoma Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Indolent Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Indolent Lymphoma. Indolent Lymphoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Indolent Lymphoma.
  • A review of the Indolent Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Indolent Lymphoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 9
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Indolent Lymphoma Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Indolent Lymphoma 13
Indolent Lymphoma Therapeutics under Development by Companies 15
Indolent Lymphoma Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Indolent Lymphoma Therapeutics Products under Development by Companies 23
Indolent Lymphoma Therapeutics Products under Investigation by Universities/Institutes 24
Companies Involved in Indolent Lymphoma Therapeutics Development 26
F. Hoffmann-La Roche Ltd. 26
Amgen Inc. 27
Sanofi-Aventis 28
Gilead Sciences, Inc. 29
Emergent BioSolutions Inc. 30
Astellas Pharma Inc. 31
Cephalon, Inc. 32
Cell Therapeutics, Inc. 33
Genmab A/S 34
Celgene Corporation 35
Accentia Biopharmaceuticals, Inc. 36
Indolent Lymphoma Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
obinutuzumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
pacritinib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BiovaxID - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
bendamustine hydrochloride - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GS-1101 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Rituximab + Gemcitabine + Oxaliplatin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Rituxan + BEAM + Autologous Stem Cell Transplantation - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
PS-341 + Alvocidib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
VR-CHOP - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 56
RAD001 + Velcade - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
rituximab - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Velcade + Rituximab - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Rituximab + Dexamethasone - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
vorinostat - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Treanda + Rituxan - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
GS 1101 + Bendamustine + Rituximab - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
GS 1101 + Bendamustine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
GS-1101 + Rituximab - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
RG7159 + Bendamustine - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Arzerra + Bendamustine - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RG7159 + CHOP - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 77
Pixuvri + Fludarabine + Dexamethasone + Rituximab - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Zevalin + Rituximab - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
dolastatin 10 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Velcade + BEAM + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 84
Vorinostat + Rituximab - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Aldesleukin + Cyclophosphamide + Therapeutic Autologous Lymphocytes - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Tumor Derived Immunoglobulin Idiotype With Keyhole Limpet Hemocyanin Conjugate Vaccine + Sargramostim + Cyclophosphamide + Vincristine + Prednisone + Doxorubicin - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 89
Treanda + Ofatumumab - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 93
Rituximab + THP-COP - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 95
binetrakin - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
ofatumumab - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
Revlimid + Rituxan - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
ofatumumab - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Zevalin + Rituxan - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
TRU-016 + Rituximab + Bendamustine - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
RG7159 + Chemotherapy - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Allogeneic Haematopoietic Stem Cell Transplantation + Fludarabine + Radiation Therapy - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
GS-1101 + Ofatumumab - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
GS-1101 + Fludarabine - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
SAR245409 + Rituximab - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
SAR245409 + Bendamustine + Rituximab - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
SAR245409 + Bendamustine - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
Fludarabine + Cyclophosphamide - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
Lenalidomide + Rituximab - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
Indolent Lymphoma Therapeutics Drug Profile Updates 130
Indolent Lymphoma Therapeutics Discontinued Products 146
Indolent Lymphoma Therapeutics - Dormant Products 147
Indolent Lymphoma Product Development Milestones 148
Featured News & Press Releases 148
Aug 17, 2011: Emergent Announces Initiation Of Phase Ib/II Study Of TRU-016 In Combination With Rituximab And Bendamustine In Subjects With Relapsed-Indolent Lymphoma 148
Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH 148
Dec 05, 2010: Calistoga Reports Positive Phase I interim Results From Combination Trial Of CAL-101 In Hematologic Malignancies 150
Dec 05, 2010: Calistoga Reports Positive Results From CAL-101 Phase I Trial In Hematologic Malignancies 151
Jun 14, 2010: Calistoga Pharmaceuticals Presents Preclinical And Clinical Data Supporting Benefit Of First In Class, Novel Mechanism Of CAL-101, An Oral Delta Isoform-Selective PI3 Kinase Inhibitor 152

Appendix 154
Methodology 154
Coverage 154
Secondary Research 154
Primary Research 154
Expert Panel Validation 154
Contact Us 155
Disclaimer 155

List of Table


Number of Products Under Development for Indolent Lymphoma, H2 2012 13
Products under Development for Indolent Lymphoma Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Investigation by Universities/Institutes, H2 2012 18
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 19
Comparative Analysis by Late Stage Development, H2 2012 20
Comparative Analysis by Mid Clinical Stage Development, H2 2012 21
Comparative Analysis by Early Clinical Stage Development, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 24
F. Hoffmann-La Roche Ltd., H2 2012 26
Amgen Inc., H2 2012 27
Sanofi-Aventis, H2 2012 28
Gilead Sciences, Inc., H2 2012 29
Emergent BioSolutions Inc., H2 2012 30
Astellas Pharma Inc., H2 2012 31
Cephalon, Inc., H2 2012 32
Cell Therapeutics, Inc., H2 2012 33
Genmab A/S, H2 2012 34
Celgene Corporation, H2 2012 35
Accentia Biopharmaceuticals, Inc., H2 2012 36
Assessment by Monotherapy Products, H2 2012 37
Assessment by Combination Products, H2 2012 38
Assessment by Stage and Route of Administration, H2 2012 40
Assessment by Stage and Molecule Type, H2 2012 42
Indolent Lymphoma Therapeutics Drug Profile Updates 130
Indolent Lymphoma Therapeutics Discontinued Products 146
Indolent Lymphoma Therapeutics Dormant Products 147

List of Chart


Number of Products under Development for Indolent Lymphoma, H2 2012 13
Products under Development for Indolent Lymphoma Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 17
Late Stage Products, H2 2012 20
Mid Clinical Stage Products, H2 2012 21
Early Clinical Stage Products, H2 2012 22
Assessment by Monotherapy Products, H2 2012 37
Assessment by Combination Products, H2 2012 38
Assessment by Route of Administration, H2 2012 39
Assessment by Stage and Route of Administration, H2 2012 40
Assessment by Molecule Type, H2 2012 41
Assessment by Stage and Molecule Type, H2 2012 42

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top